Chronic Kidney Disease Clinical Trial
— ZEBRAOfficial title:
A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma
Verified date | October 2017 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many patients with scleroderma have damage to their kidneys caused by the disease. There is
limited evidence for treatments to prevent this damage or stop it progressing. Blocking a
substance in the blood called endothelin has helped treat some aspects of scleroderma. The
purpose of this study is to see how effective a new endothelin blocker called Zibotentan is
in treating patients who have scleroderma and have gone on to develop reduced kidney function
as a complication. It will be given in addition to the accepted treatments used for
scleroderma. There will be three parts to this study each for a different group of patients:
- ZEBRA 1 for patients with mild or moderate kidney disease caused by scleroderma
- ZEBRA 2A for patients with a more severe, acute form of kidney disease caused by
scleroderma (scleroderma renal crisis) who do not require dialysis
- ZEBRA 2B for patients who have had scleroderma renal crisis and are on dialysis
Status | Completed |
Enrollment | 27 |
Est. completion date | October 2017 |
Est. primary completion date | October 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adults with scleroderma and: 2. CKD 2/3 (ZEBRA 1) 3. Renal crisis not on dialysis (ZEBRA 2A) 4. Renal crisis on dialysis (ZEBRA 2B) Exclusion Criteria: 1. Previous use of an endothelin receptor antagonist within 3 months of the study start 2. Significant abnormalities in liver function testing (ALT, ALP, Bilirubin) more than three times upper limit of normal) 3. Patients with body weight <40kg. 4. Patients with conditions which prevent compliance with the protocol or failure to adhere to therapy. 5. Patients with any other life threatening condition. 6. Patients with known hypersensitivity to Zibotentan or its excipients 7. Previous history of epilepsy or other CNS AEs, neurologic symptoms or signs consistent with acute or evolving spinal cord compression, and CNS metastases 8. Patients with a baseline left ventricular ejection fraction < 40% (prior to any scleroderma renal crisis), patients with acute myocardial infarction within six months or patients who are judged by the trial clinician to be at unacceptable risk from cardiac complications. 9. History of chronic alcohol or drug abuse or any condition associated with poor compliance as judged by the investigator 10. Patients receiving cyclosporin A within 1 week of screening or expecting to receive this agent during the study. 11. Patients who have received an investigational agent in the month prior to screening. These patients may be eligible if after a month of washout period, they are still within 112 months of the onset of the Scleroderma renal crisis. 12. Active malignancy or neoplastic disease in the previous 12 months 13. Women who rely on oestrogencontaining contraceptives (due to potential drug interaction with Zibotentan). 14. Females who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Free London NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
University College, London | Medical Research Council |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | sVCAM 1 soluble Vascular Cell Adhesion Molecule | sVCAM1 is a biomarker of renal involvement in scleroderma | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |